Dallas, TX - April 14, 2026
We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of…
https://etira.life/wp-content/uploads/2026/04/MC-1.png25122532Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-04-14 15:17:312026-04-14 15:17:31Etira chosen for Mass Challenge!
San Antonio, TX - March 23, 2026.We are pleased to present our new open-access paper in Biomolecules (link here).Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of breast…
https://etira.life/wp-content/uploads/2026/03/1565c5da-3105-4c13-949d-0e159581542e.jpg521930Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-03-23 11:40:282026-03-23 11:40:28ERX-41 shows activity in rare aggressive Breast Cancer subtype
San Antonio TX, February 06, 2026Introducing ERX-208 - our supercharged ERX-41 analog for ovarian cancer!Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher…
https://etira.life/wp-content/uploads/2026/03/oncogene-logo-2.jpg400495Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-03-06 08:08:362026-03-23 18:50:50Optimization of LIPA targeting in Ovarian Cancer
Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.
https://etira.life/wp-content/uploads/2026/01/Dr-Annalisa.jpg500500Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-01-09 08:00:542026-03-06 07:50:36Etira Board Member recognized in 2026 King’s New Year Honors
San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.
Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…
https://etira.life/wp-content/uploads/2025/07/australia-rd-savings-etira.jpg14501530Carlton Hoythttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngCarlton Hoyt2025-07-16 08:27:302026-01-02 10:45:53Etira CEO Featured In Clinical Leader for R&D Efficiency
Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical…
https://etira.life/wp-content/uploads/2024/08/clinical-trial-sign.jpg7131000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-06-26 13:14:192026-01-02 10:58:01Progress in ERX-315 Phase 1 Clinical Trial
Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South Wales. The…
Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…
https://etira.life/wp-content/uploads/2025/04/AACR-2025-graphic-2K-e1746033763417.jpg10171083Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-04-30 11:25:242025-04-30 12:09:39Research on Etira drugs win awards at AACR 2025
Chicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…
https://etira.life/wp-content/uploads/2025/04/Unknown.png14001266Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-04-24 14:25:482026-01-02 11:01:32Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Etira chosen for Mass Challenge!
NewsERX-41 shows activity in rare aggressive Breast Cancer subtype
NewsOptimization of LIPA targeting in Ovarian Cancer
NewsEtira Board Member recognized in 2026 King’s New Year Honors
NewsEtira Founder’s Scientific Journey Highlighted
NewsEtira CEO Featured In Clinical Leader for R&D Efficiency
NewsProgress in ERX-315 Phase 1 Clinical Trial
NewsEtira Expands Clinical Trial Sites
NewsResearch on Etira drugs win awards at AACR 2025
NewsPreclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
News